JP2014524482A5 - - Google Patents

Download PDF

Info

Publication number
JP2014524482A5
JP2014524482A5 JP2014527356A JP2014527356A JP2014524482A5 JP 2014524482 A5 JP2014524482 A5 JP 2014524482A5 JP 2014527356 A JP2014527356 A JP 2014527356A JP 2014527356 A JP2014527356 A JP 2014527356A JP 2014524482 A5 JP2014524482 A5 JP 2014524482A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
haloalkyl
halo
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/052572 external-priority patent/WO2013029057A2/en
Publication of JP2014524482A publication Critical patent/JP2014524482A/ja
Publication of JP2014524482A5 publication Critical patent/JP2014524482A5/ja
Pending legal-status Critical Current

Links

JP2014527356A 2011-08-25 2012-08-27 神経変性疾患を処置する組成物及び方法 Pending JP2014524482A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527584P 2011-08-25 2011-08-25
US61/527,584 2011-08-25
PCT/US2012/052572 WO2013029057A2 (en) 2011-08-25 2012-08-27 Compositions and methods for treating neurodegenerative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017133600A Division JP2017206545A (ja) 2011-08-25 2017-07-07 神経変性疾患を処置する組成物及び方法

Publications (2)

Publication Number Publication Date
JP2014524482A JP2014524482A (ja) 2014-09-22
JP2014524482A5 true JP2014524482A5 (cg-RX-API-DMAC7.html) 2016-03-31

Family

ID=47747105

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014527356A Pending JP2014524482A (ja) 2011-08-25 2012-08-27 神経変性疾患を処置する組成物及び方法
JP2017133600A Pending JP2017206545A (ja) 2011-08-25 2017-07-07 神経変性疾患を処置する組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017133600A Pending JP2017206545A (ja) 2011-08-25 2017-07-07 神経変性疾患を処置する組成物及び方法

Country Status (11)

Country Link
US (1) US20170197977A9 (cg-RX-API-DMAC7.html)
EP (1) EP2747759A4 (cg-RX-API-DMAC7.html)
JP (2) JP2014524482A (cg-RX-API-DMAC7.html)
CN (1) CN104053435A (cg-RX-API-DMAC7.html)
AU (1) AU2012298614A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014004414A2 (cg-RX-API-DMAC7.html)
CA (1) CA2846604A1 (cg-RX-API-DMAC7.html)
HK (1) HK1202248A1 (cg-RX-API-DMAC7.html)
IL (1) IL231157A0 (cg-RX-API-DMAC7.html)
RU (1) RU2014111079A (cg-RX-API-DMAC7.html)
WO (1) WO2013029057A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010118055A1 (en) 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
RU2012107457A (ru) 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
WO2015009742A2 (en) 2013-07-15 2015-01-22 Board Of Regents, The University Of Texas System Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
WO2017041037A1 (en) * 2015-09-04 2017-03-09 The Trustees Of Columbia University In The City Of New York Disruption of the interaction between amyloid beta peptide and dietary lipids
CA3022432A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
CN108226319A (zh) * 2016-12-22 2018-06-29 亚宝药业集团股份有限公司 一种检测卡巴拉汀贴剂中光学异构体的方法
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
CA3212092A1 (en) * 2021-03-19 2022-09-22 Cognition Therapeutics, Inc. Compositions and methods for treating neurologic diseases
CN114882940B (zh) * 2022-03-28 2022-11-08 北京玻色量子科技有限公司 一种基于相干伊辛机的分子对接方法和装置
WO2025181805A1 (en) * 2024-02-27 2025-09-04 Prilenia Neurotherapeutics Ltd. Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof
WO2026030341A1 (en) 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease
WO2026136732A1 (en) 2024-12-18 2026-06-25 Cognition Therapeutics, Inc. Compositions and methods for the treatment of dementia with lewy bodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA732136B (en) * 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
FI81713C (fi) * 1983-01-31 1990-12-10 Lilly Co Eli Foerfarande och djurfoderpremix foer befraemjande av tillvaexten, foerbaettring av utnyttjandegraden av foder eller minskning av fetthalten i koett hos ett husdjur.
US4697024A (en) * 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
CA2071897A1 (en) * 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DE4000610A1 (de) * 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) * 1990-02-23 1998-10-30 塩野義製薬株式会社 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
JPH045266A (ja) * 1990-04-24 1992-01-09 Toyo Pharma- Kk ドパミン誘導体の製造方法
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
DE10027151A1 (de) * 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
CN101121670A (zh) * 2007-09-11 2008-02-13 上海紫源制药有限公司 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法
WO2010088450A2 (en) * 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
WO2010118055A1 (en) * 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
RU2012107457A (ru) * 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
US20130071330A1 (en) * 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2012027548A1 (en) * 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Compounds and methods for prevention and treatment of alzheimer's and other diseases
SG192596A1 (en) * 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
US20140378460A1 (en) * 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease

Similar Documents

Publication Publication Date Title
JP2014529613A5 (cg-RX-API-DMAC7.html)
RU2014111079A (ru) Композиции и способы для лечения нейродегенеративного заболевания
ES2530780T3 (es) Composiciones y métodos para el tratamiento de trastornos oculares
NO20090910L (no) Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister
ECSP088499A (es) Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia
RU2016134677A (ru) Композиции изоиндолина и способы лечения нейродегенеративного заболевания
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
EP2379064A4 (en) LONG CIRCULATING NANOTEHICLES FOR THE DELAYED RELEASE OF THERAPEUTIC AGENTS
CL2014000659A1 (es) Compuestos derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida, antagonistas del receptor de orexina; composicion farmaceutica; y su uso para la prevencion o el tratamiento de una enfermedad seleccionada del grupo que consiste en trastornos de ansiedad, adiccion, animicos y del apetito.
PE20140381A1 (es) Dispersiones solidas extruidas por fusion que contienen un agente inductor de apoptosis
JP2016520618A5 (cg-RX-API-DMAC7.html)
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
AR054814A1 (es) Derivados de piridazina
AR059356A1 (es) Nuevos radioligandos
AR051475A1 (es) Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
ATE495167T1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
AR076362A1 (es) Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras.
CL2009001146A1 (es) Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis.
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты
EP1617806A4 (en) SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS
AR053435A1 (es) Derivados de 5-amminoindol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un madicamento para el tratamiento de enfermedades asociadas a la modulacion de receptores h3.